PD16-08 EVOLUTION: A EUROPEAN REGISTRY EVALUATING MANAGEMENT PRACTICES OF PHARMACOLOGICALLY TREATED PATIENTS WITH LUTS ASSOCIATED WITH BPH. SYMPTOMATIC IMPROVEMENT, PROGRESSION AND TREATMENT DISCONTINUATION RESULTS. A COMPARISON BETWEEN EUROPEAN COUNTRIES.

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-Surgical Therapy1 Apr 2015PD16-08 EVOLUTION: A EUROPEAN REGISTRY EVALUATING MANAGEMENT PRACTICES OF PHARMACOLOGICALLY TREATED PATIENTS WITH LUTS ASSOCIATED WITH BPH. SYMPTOMATIC IMPROVEMENT, PROGRESSION AND TREATMENT DISCONTINUATION RESULTS. A COMPARISON BETWEEN EUROPEAN COUNTRIES. Andrea Tubaro, Richard Berges, Mark Speakman, Alexandre de la Taille, Luis Martínez-Piñeiro, Anup Patel, Christien Caris, and Wim Witjes Andrea TubaroAndrea Tubaro More articles by this author , Richard BergesRichard Berges More articles by this author , Mark SpeakmanMark Speakman More articles by this author , Alexandre de la TailleAlexandre de la Taille More articles by this author , Luis Martínez-PiñeiroLuis Martínez-Piñeiro More articles by this author , Anup PatelAnup Patel More articles by this author , Christien CarisChristien Caris More articles by this author , and Wim WitjesWim Witjes More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1292AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Information on pharmacological treatment practices and outcomes in men with LUTS/BPH treated in real-life is sparse. We report practices and outcomes of men pharmacologically treated for their LUTS/BPH. METHODS A total of 2175 men were enrolled in 5 European countries by GPs/urologists. 337 men were not evaluable. 575 untreated men (UM) with a IPSS >7 and 1263 treated men (TM) (mean IPSS 12.3) commenced pharmacological treatment and were allowed to stop or change the type of treatment. Treatment discontinuation (DT), symptom improvement (SI) - defined as IPSS reduction >2 and clinical progression (CP) - defined as worsening of symptoms (IPSS increase >3), urinary retention, recurrent urinary tract infection, renal insufficiency, incontinence or other types of progression - were evaluated amongst treatment categories and countries. RESULTS UM and TM started with the following treatments: 69% and 64% alpha-blockers (ABs); 16% and 5% phytotherapeutics; 4% and 7% 5-ARInhibitors (5-ARIs); 8% and 17% ABs combined with 5-ARIs (AB+5-ARI), and 3% and 7% with others. There were relevant differences between countries. In UM, the percentages of patients who DT were low in Germany(17%), Italy(7%), and Spain(12%) and higher in France(29%) and UK(45%). The reasons for DT were related to the type of medication. In UM treated with ABs; phytotherapeutics; 5-ARIs and AB+5-ARI treatments were discontinued in 20%; 18%, 19% and 9%. The main reason for DT in UM was lack of efficacy for ABs(10%) and phytotherapeutics(15%) versus 6 and 2% for 5-ARIs and AB+5-ARI. The overall proportion SI in UM at M24 was 0.70. In UM treated with phytotherapeutics, proportions of men with SI were less compared to other treatments. Between countries, proportions and 95%CIs SI were overlapping but Spain had less SI compared to Italy. The proportions with CP for UM and TM at M24 were 0.16 and 0.17, respectively. UK had clearly higher proportions CP compared to the other countries while IPSS scores and flowrates at baseline were not significantly different. CONCLUSIONS The real life data from this registry indicate that, except for UM treated with phytotherapeutics who experienced less SI, there were no significant differences in SI or CP between treatment categories. There was less SI in Spain compared to Italy and higher CP in UK. Pharmacological treatment management and -discontinuation proportions differed significantly between European countries. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e332-e333 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Andrea Tubaro More articles by this author Richard Berges More articles by this author Mark Speakman More articles by this author Alexandre de la Taille More articles by this author Luis Martínez-Piñeiro More articles by this author Anup Patel More articles by this author Christien Caris More articles by this author Wim Witjes More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...